Allergan has acquired Topokine Therapeutics, a privately held, clinical-stage biotechnology company focused on developing topical medicines for fat reduction, for an upfront payment of $85 million and success-based development and sales milestones for XAF5, a topical agent in late-stage development for the treatment of steatoblepharon, also known as under-eye bags.

Applied to the lower eyelids once nightly, XAF5 penetrates the skin and acts pharmacologically on fat cells to shrink under-eye bags. An estimated 40 million Americans have steatoblepharon, which can make the face look older, tired, stressed or sad.

Source: Allergan